[Translation] Phase IIb clinical study to evaluate the effectiveness and safety of Yinshen granules in the treatment of angina pectoris (Qi deficiency and blood stasis syndrome) in coronary heart disease

探索银参颗粒治疗冠心病心绞痛（气虚血瘀证）改善心脏耐力的有效性以及安全性。

[Translation]

To explore the effectiveness and safety of Yinshen Granules in treating angina pectoris of coronary heart disease (Qi deficiency and blood stasis syndrome) and improving cardiac endurance.

Start Date04 Sep 2013

Sponsor / Collaborator

Jiangsu Simcere Pharmaceutical Co., Ltd.

[+1]

100 Clinical Results associated with Yinshen Granules

100 Translational Medicine associated with Yinshen Granules

100 Patents (Medical) associated with Yinshen Granules

Literatures (Medical) associated with Yinshen Granules

31 Dec 2024·Renal Failure

Effects of soluble Klotho and Wnt/β-catenin signaling pathway in vascular calcification in chronic kidney disease model rats and the intervention of Shenyuan granules

Article

Author: Wang, Changjiang ; Zou, Xinrong ; Lin, Lamei ; Deng, Danfang ; Wang, Xiaoqin ; Wang, Lan ; Huang, Shenghua

OBJECTIVEThis study aimed to investigate the effect of the soluble Klotho (sKlotho)/Wnt/β-catenin signaling pathway on vascular calcification in rat models of chronic kidney disease (CKD) and the intervention effect of Shenyuan granules.METHODSRats with 5/6 nephrectomy and high phosphorus feeding were used to establish the vascular calcification model. The rats were given gradient doses of Shenyuan granules aqueous solution and calcitriol solution by gavage for 8 weeks, which were divided into experimental group and positive control group.RESULTSThe 5/6 nephrectomy combined with high phosphorus feeding induced thoracic aortic calcification in rats. Shenyuan granules intervention increased the serum sKlotho level, inhibited the mRNA and protein expression of Wnt1, β-catenin, and Runx2 in the thoracic aorta, and alleviated thoracic aortic media calcification in rats.CONCLUSIONShenyuan granules may partially regulate the Wnt/β-catenin signaling pathway via serum sKl to interfere with the expression of Runx2, thereby improving vascular calcification in CKD.

100 Deals associated with Yinshen Granules

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Angina Pectoris	Phase 2	China	Jiangsu Simcere Pharmaceutical Co., Ltd.	04 Sep 2013
Angina Pectoris	Phase 2	China	Suzhou Youseen New Drug R&D Co. Ltd.	04 Sep 2013

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Yinshen Granules

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation